The use of SGLT2 inhibitors in patients with heart failure is associated with an increase in the co-peptin level, a marker for AVP release, which promotes water conservation in the setting of the osmotic diuretic effect of glycosuria and prevents a significant increase in urine volume [32]. The gene discussed is SLC5A2; the disease is heart failure.